OCA at 06:29, 22 April 2026

2026-04-22T06:29:30Z

← Older revision		Revision as of 06:29, 22 April 2026
Line 1:		Line 1:
	~~'''Unreleased structure'''~~

	~~The entry~~ 9put is ~~ON HOLD until Paper Publication~~		==HRAS complex with UM0152535 compound==
			<StructureSection load='9put' size='340' side='right'caption='[[9put]], [[Resolution\|resolution]] 2.00Å' scene=''>
	~~Authors~~: Jo, C., ~~Lavoie~~, H., ~~Therrien~~, M.		== Structural highlights ==
			<table><tr><td colspan='2'>[[9put]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9PUT OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9PUT FirstGlance]. <br>
	~~Description~~: HRAS complex with ~~UM0152535 compound~~		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2Å</td></tr>
	[[Category: ~~Unreleased~~ Structures]]		<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=8G2:(4-methoxycarbonylphenyl)methylazanium'>8G2</scene>, <scene name='pdbligand=A1CK7:3-amino-3-methylbutanoic+acid'>A1CK7</scene>, <scene name='pdbligand=DPR:D-PROLINE'>DPR</scene>, <scene name='pdbligand=DTR:D-TRYPTOPHAN'>DTR</scene>, <scene name='pdbligand=GDP:GUANOSINE-5-DIPHOSPHATE'>GDP</scene>, <scene name='pdbligand=IIL:ISO-ISOLEUCINE'>IIL</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr>
	[[Category: ~~Therrien, M~~]]		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9put FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9put OCA], [https://pdbe.org/9put PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9put RCSB], [https://www.ebi.ac.uk/pdbsum/9put PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9put ProSAT]</span></td></tr>
	[[Category: Lavoie, H]]		</table>
	[[Category: ~~Jo, C~~]]		== Disease ==
			[https://www.uniprot.org/uniprot/RASH_HUMAN RASH_HUMAN] Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:[https://omim.org/entry/218040 218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.<ref>PMID:16170316</ref> <ref>PMID:16329078</ref> <ref>PMID:16443854</ref> <ref>PMID:17054105</ref> <ref>PMID:18247425</ref> <ref>PMID:18039947</ref> <ref>PMID:19995790</ref> Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:[https://omim.org/entry/218040 218040]. CMEMS is a variant of Costello syndrome.<ref>PMID:17412879</ref> Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:[https://omim.org/entry/607464 607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms. Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:[https://omim.org/entry/109800 109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).<ref>PMID:1459726</ref> Defects in HRAS are the cause of Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:[https://omim.org/entry/163200 163200]. A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis.<ref>PMID:22683711</ref>
			== Function ==
			[https://www.uniprot.org/uniprot/RASH_HUMAN RASH_HUMAN] Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.<ref>PMID:14500341</ref> <ref>PMID:9020151</ref> <ref>PMID:12740440</ref>
			== References ==
			<references/>
			__TOC__
			</StructureSection>
			[[Category: Homo sapiens]]
			[[Category: Large Structures]]
			[[Category: Synthetic construct]]
			[[Category: Jo C]]
			[[Category: Lavoie H]]
			[[Category: Therrien M]]

OCA at 09:03, 3 September 2025

2025-09-03T09:03:33Z

← Older revision		Revision as of 09:03, 3 September 2025
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

	The entry 9put is ON HOLD		The entry 9put is ON HOLD until Paper Publication

	Authors: Jo, C., Lavoie, H., Therrien, M.		Authors: Jo, C., Lavoie, H., Therrien, M.
Line 7:		Line 7:
	Description: HRAS complex with UM0152535 compound		Description: HRAS complex with UM0152535 compound
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
			[[Category: Therrien, M]]
			[[Category: Lavoie, H]]
	[[Category: Jo, C]]		[[Category: Jo, C]]
	~~[[Category: Lavoie, H]]~~
	~~[[Category: Therrien, M]]~~

OCA: Protected "9put" [edit=sysop:move=sysop]

2025-08-06T04:20:29Z

Protected "9put" [edit=sysop:move=sysop]

← Older revision	Revision as of 04:20, 6 August 2025
(No difference)

OCA: New page: '''Unreleased structure''' The entry 9put is ON HOLD Authors: Jo, C., Lavoie, H., Therrien, M. Description: HRAS complex with UM0152535 compound Category: Unreleased Structures [[C...

2025-08-06T04:20:28Z

New page: '''Unreleased structure''' The entry 9put is ON HOLD Authors: Jo, C., Lavoie, H., Therrien, M. Description: HRAS complex with UM0152535 compound Category: Unreleased Structures [[C...

New page

'''Unreleased structure'''

The entry 9put is ON HOLD

Authors: Jo, C., Lavoie, H., Therrien, M.

Description: HRAS complex with UM0152535 compound
[[Category: Unreleased Structures]]
[[Category: Jo, C]]
[[Category: Lavoie, H]]
[[Category: Therrien, M]]

9put - Revision history

OCA at 06:29, 22 April 2026

OCA at 09:03, 3 September 2025

OCA: Protected "9put" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 9put is ON HOLD Authors: Jo, C., Lavoie, H., Therrien, M. Description: HRAS complex with UM0152535 compound Category: Unreleased Structures [[C...